Trial Profile
A Phase IIa, Multicenter, Open-Label Study Designed to Evaluate the Safety and Efficacy of Escalating Doses of BL-8040 in Adult Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Motixafortide (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Proof of concept
- Sponsors BioLineRx
- 03 Dec 2020 Results published in the Cancer
- 18 Jun 2018 According to a BioLineRx media release, data from the trial presented at the 23rd Annual Congress of the European Hematology Association (EHA) 2018.
- 18 Jun 2018 Results published in the BioLineRx Media Release